159 related articles for article (PubMed ID: 38491829)
1. A survey of carboplatin desensitization therapy in Japan: A multicenter retrospective study.
Komatsu H; Matsumoto K; Morita M; Nagasawa T; Nishio H; Suzuki J; Nishio S; Kobara H; Yunokawa M; Ariyoshi K; Hirayama T; Tokunaga H; Ukita M; Yoriki K; Mori-Uchino M; Furusawa A; Togami S; Nakamura H; Ishikawa M; Satoh T
Cancer Med; 2024 Mar; 13(5):e6968. PubMed ID: 38491829
[TBL] [Abstract][Full Text] [Related]
2. Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin.
Li Q; Cohn D; Waller A; Backes F; Copeland L; Fowler J; Salani R; O'Malley D
Gynecol Oncol; 2014 Oct; 135(1):90-4. PubMed ID: 25110329
[TBL] [Abstract][Full Text] [Related]
3. Investigation of Hypersensitivity Reactions in Carboplatin Desensitization Therapy.
Shibata N; Kawakami K; Hisanori S; Kobayashi K; Yunokawa M; Kanao H; Taki I; Murase R; Kamei D; Yamaguchi M
Anticancer Res; 2022 Feb; 42(2):1091-1097. PubMed ID: 35093911
[TBL] [Abstract][Full Text] [Related]
4. 4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study.
Takase N; Matsumoto K; Onoe T; Kitao A; Tanioka M; Kikukawa Y; Yamaguchi S; Fujiwara K; Negoro S
Int J Clin Oncol; 2015 Jun; 20(3):566-73. PubMed ID: 25030546
[TBL] [Abstract][Full Text] [Related]
5. Management of hypersensitivity reactions to Carboplatin and Paclitaxel in an outpatient oncology infusion center: a 5-year review.
Banerji A; Lax T; Guyer A; Hurwitz S; Camargo CA; Long AA
J Allergy Clin Immunol Pract; 2014; 2(4):428-33. PubMed ID: 25017531
[TBL] [Abstract][Full Text] [Related]
6. Incidence of Carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies.
Koshiba H; Hosokawa K; Kubo A; Miyagi Y; Oda T; Miyagi Y; Watanabe A; Honjo H
Int J Gynecol Cancer; 2009 Apr; 19(3):460-5. PubMed ID: 19407575
[TBL] [Abstract][Full Text] [Related]
7. Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study.
Altwerger G; Gressel GM; English DP; Nelson WK; Carusillo N; Silasi DA; Azodi M; Santin A; Schwartz PE; Ratner ES
Gynecol Oncol; 2017 Jan; 144(1):77-82. PubMed ID: 27789084
[TBL] [Abstract][Full Text] [Related]
8. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.
Hesterberg PE; Banerji A; Oren E; Penson RT; Krasner CN; Seiden MV; Wong JT
J Allergy Clin Immunol; 2009 Jun; 123(6):1262-7.e1. PubMed ID: 19501233
[TBL] [Abstract][Full Text] [Related]
9. Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study.
Gomez R; Harter P; Lück HJ; Traut A; Kommoss S; Kandel M; du Bois A
Int J Gynecol Cancer; 2009 Oct; 19(7):1284-7. PubMed ID: 19823066
[TBL] [Abstract][Full Text] [Related]
10. Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions.
Vetter MH; Khan A; Backes FJ; Bixel K; Cohn DE; Copeland LJ; Fowler JM; Salani R; Li Q; O'Malley DM
Gynecol Oncol; 2019 Feb; 152(2):316-321. PubMed ID: 30503265
[TBL] [Abstract][Full Text] [Related]
11. Desensitization strategy for hypersensitivity reactions to carboplatin in five patients with gynecological cancer.
Toyohara Y; Sone K; Nishida H; Taguchi A; Miyamoto Y; Tanikawa M; Mori M; Tsuruga T; Matsumoto Y; Oda K; Osuga Y; Fujii T
J Obstet Gynaecol Res; 2020 Nov; 46(11):2298-2304. PubMed ID: 32830407
[TBL] [Abstract][Full Text] [Related]
12. Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer.
Altwerger G; Florsheim EB; Menderes G; Black J; Schwab C; Gressel GM; Nelson WK; Carusillo N; Passante T; Huang G; Litkouhi B; Azodi M; Silasi DA; Santin A; Schwartz PE; Ratner ES
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2449-2456. PubMed ID: 30255380
[TBL] [Abstract][Full Text] [Related]
13. Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.
Okayama T; Ishikawa T; Sugatani K; Yoshida N; Kokura S; Matsuda K; Tsukamoto S; Ihara N; Kuriu Y; Nakanishi M; Nakamura T; Kamada K; Katada K; Uchiyama K; Takagi T; Handa O; Konishi H; Yagi N; Naito Y; Otsuji E; Hosoi H; Miki T; Itoh Y
Clin Ther; 2015 Jun; 37(6):1259-69. PubMed ID: 25862137
[TBL] [Abstract][Full Text] [Related]
14. Platin desensitizations in thoracic malignancies and risk factors for breakthrough reactions.
Buhari GK; Kalkan İK; Ateş H; Bahçecioğlu SN; Demir Ş; Yeşilkaya S; Solak GTV; Aksu K; Erkekol FÖ
Allergol Immunopathol (Madr); 2023; 51(2):130-136. PubMed ID: 36916098
[TBL] [Abstract][Full Text] [Related]
15. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK
Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
[TBL] [Abstract][Full Text] [Related]
16. A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity.
Chung SJ; Kang SY; Kang RY; Kim YC; Lee KH; Kim TY; Han SW; Kang HR
Cancer Chemother Pharmacol; 2018 Nov; 82(5):777-785. PubMed ID: 30105458
[TBL] [Abstract][Full Text] [Related]
17. [Clinical analysis of hypersensitivity reaction of platinum in ovarian cancer and cervical cancer patients].
Li L; Wu M; Yang JX; Wan XR; Huang HF; Pan LY; Shen K; Lang JH; Xiang Y
Zhonghua Fu Chan Ke Za Zhi; 2016 Nov; 51(11):825-831. PubMed ID: 27916065
[No Abstract] [Full Text] [Related]
18. [Hypersensitivity reactions to carboplatin and paclitaxel - our five-years experiences].
Rezáč A; Jílek P; Rezáčová V; Skapinec P; Sedláková I; Tošner J; Spaček J
Ceska Gynekol; 2013 Dec; 78(6):514-21. PubMed ID: 24372428
[TBL] [Abstract][Full Text] [Related]
19. Desensitization in patients with hypersensitivity to platinum and taxane in gynecological cancers.
Zwimpfer TA; Scherer K; Schötzau A; Heinzelmann-Schwarz V; Hartmann K; Vetter M; Montavon C
Cancer Med; 2023 Dec; 13(1):. PubMed ID: 38140783
[TBL] [Abstract][Full Text] [Related]
20. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.
Moon DH; Lee JM; Noonan AM; Annunziata CM; Minasian L; Houston N; Hays JL; Kohn EC
Br J Cancer; 2013 Aug; 109(4):1072-8. PubMed ID: 23867999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
